rituximab
Orphan Drug Cold Chain RequiredFDA Approved
Description
Rituximab is a chimeric monoclonal antibody targeting CD20-positive B cells, approved for various hematologic malignancies and autoimmune conditions. It has been used off-label in steroid-resistant nephrotic syndrome type 1 (congenital nephrotic syndrome) and shows promise in certain cases of treatment-resistant disease. The drug depletes B lymphocytes, reducing antibody-mediated kidney damage.
Indications & Therapeutic Use
non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, steroid-resistant nephrotic syndrome
Linked Diseases:
Pemphigus vegetans
L10.1
diffuse large B-cell lymphoma
C83.3D016403
Hodgkin lymphoma
D006689
autoimmune pancreatitis
D000081012
nephrotic syndrome type 1
C535761
Global Availability (11 countries)
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
rituximab
| Generic Name | rituximab |
| Brands | 1 brand available |
| Active Ingredient | rituximab |
| Drug Class | non-Hodgkin lymphoma |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion 10mg/mL (100mg/10mL, 500mg/50mL vials) |
| Medical Code | L01FA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00498368 |
| Countries | 11 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations12 Validated Nodes